On October 13, CANSINOBIO fell 5.5% in regular trading, trading at 31.26 HKD, with turnover of 90.44 million HKD.

Prior to this session, the stock experienced a sharp rally in late September driven by positive sentiment around mRNA cancer vaccine prospects, followed by profit-taking after Moderna's sharp decline and a downgrade from Citigroup pressured vaccine names across the market.

In the broader biotechnology sector, peers also traded lower, including AKESO down 3.36%, BEONE MEDICINES down 1.41%, INNOVENT BIO down 2.5%, and METIS TECHBIO-P down 12.83%.

CANSINOBIO is a China-based clinical-stage vaccine company, with products targeting meningitis, pertussis, and pneumonia.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)